Literature DB >> 30212682

Treatment of atherosclerosis by traditional Chinese medicine: Questions and quandaries.

Chuan Wang1, Manabu Niimi2, Teruo Watanabe3, Yanli Wang4, Jingyan Liang5, Jianglin Fan6.   

Abstract

Atherosclerosis and its complications, such as myocardial infarction and stroke, are the major causes of morbidity and mortality, and development of effective therapies for both prevention and treatment of this disease is critically important. Currently, there are many drugs available for atherosclerotic disease, but the lipid-lowering drugs statins are still the first-choice for treatment of hypercholesterolemia, a major risk factor for atherosclerosis. On the other hand, traditional Chinese medicines, mainly Chinese herbal medicines (CHM), have been widely used in China and in other Asian countries for the treatment of atherosclerotic diseases. Although many CHMs have been reported to be effective for treating atherosclerotic diseases for more than two thousand years, there are still many difficulties for their use, such as lack of scientific evidence assessed by rigorous clinical trials, complicated components and unclear pharmacological mechanisms, which often hamper the widespread use of CHMs in Western countries. Due to these concerns, CHMs are usually considered as complimentary or alternative treatment for atherosclerotic diseases. In this review, we provide an overview of the pathophysiology of atherosclerosis viewed by Western and traditional Chinese medicine, summarize pros and cons on the efficacy of CHMs for atherosclerosis and discuss what is necessary for CHM use to spread to Western societies.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atherosclerosis; CHD; CHM; CVD; Cardiovascular disease; Chinese herbal medicine; Chinese herbal medicines; Coronary heart disease; RCT; Randomized clinical trials; TCM; Traditional Chinese medicine

Year:  2018        PMID: 30212682     DOI: 10.1016/j.atherosclerosis.2018.08.039

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  27 in total

1.  Curcumin alleviates lipopolysaccharides-induced inflammation and apoptosis in vascular smooth muscle cells via inhibition of the NF-κB and JNK signaling pathways.

Authors:  Haohang Ruan; Qing Huang; Benting Wan; Ming Yang
Journal:  Inflammopharmacology       Date:  2022-03-01       Impact factor: 4.473

2.  LncRNA HCG11 Accelerates Atherosclerosis via Regulating the miR-224-3p/JAK1 Axis.

Authors:  Hua Zhou; Wei-Hong Song
Journal:  Biochem Genet       Date:  2022-08-05       Impact factor: 2.220

3.  Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model.

Authors:  Yihai Liu; Mingyue Wu; Biao Xu; Lina Kang
Journal:  J Inflamm Res       Date:  2021-05-31

4.  Antiatherosclerotic effects of corilagin via suppression of the LOX-1/MyD88/NF-κB signaling pathway in vivo and in vitro.

Authors:  Bo He; Deyun Chen; Xiaochao Zhang; Renhua Yang; Yuan Yang; Peng Chen; Zhiqiang Shen
Journal:  J Nat Med       Date:  2022-01-22       Impact factor: 2.343

5.  Berberine Attenuates Arterial Plaque Formation in Atherosclerotic Rats with Damp-Heat Syndrome via Regulating Autophagy.

Authors:  Xiao Ke; Yiteng Huang; Liang Li; Fuya Xin; Luhua Xu; Yuangui Zhang; Zhicong Zeng; Fengxia Lin; Yinzhi Song
Journal:  Drug Des Devel Ther       Date:  2020-06-23       Impact factor: 4.162

6.  Piceatannol inhibits pyroptosis and suppresses oxLDL-induced lipid storage in macrophages by regulating miR-200a/Nrf2/GSDMD axis.

Authors:  Zhongyuan Mu; Hongling Zhang; Peng Lei
Journal:  Biosci Rep       Date:  2020-09-30       Impact factor: 3.840

7.  Pharmacological Network Reveals the Active Mechanism of Qi-Replenishing, Spleen-Strengthening, Phlegm-Dispelling, and Blood-Nourishing Fufang on Coronary Heart Disease.

Authors:  Fan Zhang; Yue Liu; Sicheng Zheng; Boyi Dang; Jianan Wang; Zhe Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2020-12-29       Impact factor: 2.629

8.  The atheroprotective roles of heart-protecting musk pills against atherosclerosis development in apolipoprotein E-deficient mice.

Authors:  Li Lu; Yating Qin; Chen Chen; Xinxin Zhang; Xiangyu Xu; Chao Lv; Xiaoning Wan; Weibin Ruan; Xiaomei Guo
Journal:  Ann Transl Med       Date:  2019-12

9.  The Enhanced Pharmacological Effects of Modified Traditional Chinese Medicine in Attenuation of Atherosclerosis Is Driven by Modulation of Gut Microbiota.

Authors:  Wenyan Ji; Ting Jiang; Zheng Sun; Fei Teng; Chenchen Ma; Shi Huang; Suhua Yan
Journal:  Front Pharmacol       Date:  2020-10-15       Impact factor: 5.810

10.  Shen-Hong-Tong-Luo Formula Attenuates Macrophage Inflammation and Lipid Accumulation through the Activation of the PPAR-γ/LXR-α/ABCA1 Pathway.

Authors:  Zepeng Zhang; Lu Zhai; Jing Lu; Sanmiao Sun; Dandan Wang; Daqing Zhao; Liwei Sun; Weimin Zhao; Xiangyan Li; Ying Chen
Journal:  Oxid Med Cell Longev       Date:  2020-10-01       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.